Wang Wen-Yao, Zhang Kuo, Zhao Wei, Gerdes A Martin, Iervasi Giorgio, Tang Yi-Da
Departments of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
J Geriatr Cardiol. 2018 Apr;15(4):290-297. doi: 10.11909/j.issn.1671-5411.2018.04.009.
Although thyroid hormone (TH) has important effects on lipid metabolism, the relationship between TH and statin responsiveness has never been investigated. We hypothesize that TH plays an important role in statin responsiveness in patients with acute myocardial infarction (AMI).
Consecutive 1091 hospitalized AMI patients in Fuwai hospital (Beijing, China) were enrolled into this current study. The study population was divided into three groups based on the intensity of statin treatment: low-intensity ( = 221), moderate-intensity ( = 712) and high-intensity ( = 158). Lipid levels were measured after statin therapy lasting for 10-14 days. The association between TH, lipid profile levels and achievement of low-density lipoprotein cholesterol (LDL-C) lowering goals was explored in patients with AMI on statin therapy.
By general linear analysis, a significant linear trend between free triiodothyronine (FT3) and LDL-C level (linear coefficient = -0.082, = 0.001) and FT3 and total cholesterol (TC) level ( = -0.105, = 0.031) was observed in the moderate-intensity statin group. A more apparent linear trend was detected in the high-intensity statin group (for LDL-C: = -0.113, = 0.005; for TC: = -0.172, = 0.029, respectively). However, no significant correlation was observed in the low-intensity statin group. Compared with the low-FT3 group (defined as FT3 < 1.79 pg/mL), the OR (95% CI) for attaining a LDL-C < 3.0mmol/L was found to be 2.217 (1.001-4.839) in the higher FT3 group (> 2.95 pg/mL). The OR (95% CI) for attaining the more intensive goal (LDL-C < 1.8mmol/L) was 2.836 (1.014-5.182).
Our study reveals that variation in FT3 levels is related to the cholesterol-lowering responsiveness of statins in AMI patients. These findings suggest that low FT3 may be a factor responsible for lack of LDL-C goal attainment and patients' poor responsiveness to statin treatment.
尽管甲状腺激素(TH)对脂质代谢有重要影响,但TH与他汀类药物反应性之间的关系从未被研究过。我们假设TH在急性心肌梗死(AMI)患者的他汀类药物反应性中起重要作用。
连续纳入中国北京阜外医院的1091例住院AMI患者。根据他汀类药物治疗强度将研究人群分为三组:低强度(n = 221)、中等强度(n = 712)和高强度(n = 158)。在他汀类药物治疗10 - 14天后测量血脂水平。探讨了接受他汀类药物治疗的AMI患者中TH、血脂谱水平与实现低密度脂蛋白胆固醇(LDL-C)降低目标之间的关联。
通过一般线性分析,在中等强度他汀类药物组中观察到游离三碘甲状腺原氨酸(FT3)与LDL-C水平(线性系数β = -0.082,P = 0.001)以及FT3与总胆固醇(TC)水平(β = -0.105,P = 0.031)之间存在显著的线性趋势。在高强度他汀类药物组中检测到更明显的线性趋势(对于LDL-C:β = -0.113,P = 0.005;对于TC:β = -0.172,P = 0.029)。然而,在低强度他汀类药物组中未观察到显著相关性。与低FT3组(定义为FT3 < 1.79 pg/mL)相比,较高FT3组(> 2.95 pg/mL)实现LDL-C < 3.0mmol/L的OR(95%CI)为2.217(1.001 - 4.839)。实现更严格目标(LDL-C < 1.8mmol/L)的OR(95%CI)为2.836(1.014 - 5.182)。
我们的研究表明,FT3水平的变化与AMI患者他汀类药物的降胆固醇反应性相关。这些发现表明,低FT3可能是导致未实现LDL-C目标以及患者对他汀类药物治疗反应不佳的一个因素。